The briefing
OncoDaily outlines ESMO 2026 updates in metastatic breast cancer, with antibody–drug conjugates advancing into first‑line therapy. The guidance emphasizes biomarker‑driven strategies, HER2‑directed maintenance, and targeted therapy combinations.
Original headline
ESMO 2026 Reshapes Metastatic Breast Cancer Treatment: ADCs Move Into First Line as Biomarkers Guide New Strategies